SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form 10-Q”), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”)..

马萨诸塞州萨默维尔（商业新闻短讯）--蓝鸟生物有限公司（Nasdaq:BLUE）今天宣布，它于2024年8月20日收到了纳斯达克股票市场有限责任公司（Nasdaq Stock Market LLC）（“Nasdaq”）的通知（“通知”），声明由于该公司尚未在截至2024年3月31日（“2024年第一季度表格10-Q”）和2024年6月30日（“2024年第二季度表格10-Q”）的每个季度提交其季度报告，因此不符合纳斯达克上市规则5250（c）（1）（“规则”），该规则要求上市公司及时向美国证券交易委员会（“SEC”）提交所有必要的定期财务报告。。

The notices have no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq.

这些通知对公司普通股在纳斯达克的上市或交易没有直接影响。

The Company previously announced on April 26, 2024, that it was not in compliance with the Rule due to the delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”). The Company subsequently submitted a plan to Nasdaq to regain compliance with the Rule on or before October 14, 2024, within 180 calendar days from the prescribed due date of its 2023 Form 10-K.

该公司此前于2024年4月26日宣布，由于延迟提交截至2023年12月31日的10-K表格年度报告（“2023表格10-K”），因此不符合该规定。该公司随后向纳斯达克提交了一份计划，在2024年10月14日或之前，在2023年10-K表格规定到期日起180个日历日内，重新遵守该规则。

Under Nasdaq rules, the Company must also file its Q1 2024 Form 10-Q and Q2 2024 Form 10-Q within this same period, and must submit an update to its plan to regain compliance by September 4, 2024..

根据纳斯达克规则，该公司还必须在同一时期内提交2024年第一季度10-Q表和2024年第二季度10-Q表，并必须在2024年9月4日之前提交计划更新。。

On March 26, 2024, bluebird announced that it will restate its consolidated financial statements as of and for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023 in its 2023 Form 10-K. As a result of the restatement, the Company is delayed in filing its 2023 Form 10-K and its Q1 2024 Form 10-Qand Q2 2024 Form 10-Q.

2024年3月26日，蓝鸟宣布将在2023年10-K表中重述截至2022年12月31日的年度以及2022年和2023年前三个季度的合并财务报表。由于重述，公司推迟提交2023年10-K表、2024年第一季度10-Q表和2024年第二季度10-Q表。

The Company is continuing to work expeditiously to complete these filings..

该公司正在继续迅速完成这些备案。。

About bluebird bio, Inc.

。

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

蓝鸟生物正在寻求治疗性基因疗法，为患者及其家人提供更多的蓝鸟日。

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years.

蓝鸟成立于2010年，十多年来一直是基因治疗的标准制定者，最初是科学先驱，现在是商业领袖。蓝鸟在将基因治疗的前景从临床研究中带到现实世界中有着无与伦比的记录，在不到两年的时间内获得了FDA对三种疗法的批准。

Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers..

今天，我们正在验证和扩展基因治疗的商业模式，并为患者、提供者和付款人提供创新的解决方案。。

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward..

蓝鸟专注于严重的遗传疾病，拥有该领域最大和最深入的离体基因治疗数据集，拥有业界领先的镰状细胞病，β-地中海贫血和脑肾上腺白质营养不良项目。我们定制设计了每种疗法，以解决疾病的根本原因，并开发了深入有效的分析方法，以了解慢病毒载体技术的安全性，并推动基因治疗领域的发展。。

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

蓝鸟作为一家独立的商业基因治疗公司，将我们的现实世界经验与对患者社区的深刻承诺以及以人为中心的文化相结合，不断开拓新的道路，吸引并培育出各种各样的专注鸟类。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, such as statements regarding the Company’s restatement of certain historical financial statements, the filing of its 2023 Form 10-K, Q1 2024 Form 10-Q and Q2 2024 Form 10-Q, and submission of an update to its plan to regain compliance with the Rule, and the expected timing thereof.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。所有不属于历史事实报表的报表都是或可能被视为前瞻性报表，例如公司对某些历史财务报表的重述、2023年10-K表、2024年第1季度10-Q表和2024年第2季度10-Q表的提交、计划更新的提交，以恢复对该规则的遵守以及预期的时间安排。

Such forward-looking statements are based on historical performance and current expectations and projections about bluebird’s future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird’s control and could cause bluebird’s future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements.

此类前瞻性陈述基于历史表现以及当前对蓝鸟未来目标、计划和目标的预期和预测，涉及内在风险、假设和不确定性，包括可能在未来几年延迟、转移或改变其中任何一个的内部或外部因素，这些因素难以预测，可能超出蓝鸟的控制范围，并可能导致蓝鸟的未来目标、计划和目标与陈述中表达或暗示的目标存在重大差异。

No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC.

不能保证前瞻性声明。本新闻稿中的前瞻性陈述应与影响蓝鸟生物业务的许多风险和不确定性一起进行评估，特别是蓝鸟生物截至2022年12月31日的年度报告10-K表中的风险因素讨论中确定的风险因素，以及随后的10-Q表季度报告、8-K表当前报告和向SEC提交的其他文件中更新的风险因素。

The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a .

本文件中包含的前瞻性声明仅在本文件发布之日做出，除非适用法律另有要求，蓝鸟生物没有义务公开更新或修订任何前瞻性声明，无论是作为。